Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Short interest is the volume of Replimune Group shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 22,885,091 shares of REPL short.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

This is a fair market value price provided by Massive. Learn more. Replimune Group (REPL) has upcoming FDA regulatory milestones for RP1 (vusolimogene oderparepvec). The table below outlines estimated ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...